Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2003
Reporting Period: Quarter ended March 31, 2003
This filing serves as a Regulation FD disclosure to announce financial results for the quarter ended March 31, 2003. The specific financial data is contained within a press release issued on April 30, 2003, which is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), the content of which is not included in the source text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended March 31, 2003.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on April 30, 2003, to disclose results of operations and financial condition.
Regulatory Note: The information provided in this 8-K, including the attached exhibits, is not deemed "filed" for purposes of the Securities Act of 1933 or the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 30, 2003) for specific revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter performance trends not detailed in this summary.
- Check for any forward-looking statements or guidance included in the full press release.
- Confirm the status of the company's liquidity and debt obligations as reported in the full financial results.